Skip to main content
HR 2148 117th Congress House Health Administrative remedies Asia Business records Canada Civil actions and liability Competition and antitrust Department of Health and Human Services Drug safety, medical device, and laboratory regulation Europe France Germany Government information and archives Government studies and investigations Health care costs and insurance Health information and medical records Inflation and prices Intellectual property Japan Licensing and registrations

Prescription Drug Price Relief Act of 2021

Introduced: March 26, 2021 Introduced by: Khanna, Ro Democratic · California See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 117th Congress ended
It never became law before the 117th Congress (2021–2022) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Oct 19, 2021
Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Mar 24, 2021
Referred to the Subcommittee on Health.
Mar 23, 2021
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Mar 23, 2021
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Prescription Drug Price Relief Act of 2021

This bill establishes a series of oversight and disclosure requirements relating to the prices of brand-name drugs.

Specifically, the bill requires the Department of Health and Human Services (HHS) to review at least annually all brand-name drugs for excessive pricing; HHS must also review prices upon petition. If any such drugs are found to be excessively priced, HHS must (1) void any government-granted exclusivity; (2) issue open, nonexclusive licenses for the drugs; and (3) expedite the review of corresponding applications for generic drugs and biosimilar biological products. HHS must also create a public database with its determinations for each drug.

Under the bill, a price is considered excessive if the domestic average manufacturing price exceeds the median price for the drug in Canada, the United Kingdom, Germany, France, and Japan. If a price does not meet this criteria, or if pricing information is unavailable in at least three of the aforementioned countries, the price is still considered excessive if it is higher than reasonable in light of specified factors, including development cost, revenue, and the size of the affected patient population.

The bill also requires drug manufacturers to report specified financial information for brand-name drugs, including research and advertising expenditures.

What's happening now October 19, 2021

Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.

 Related & companion bills 1
  • S 909 Identical bill Prescription Drug Price Relief Act of 2021
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 4
 Cosponsors 16
All 16 Democratic 13
Bush, Cori
· Mar 26, 2021
 D
DeSaulnier, Mark
California · Mar 26, 2021
DEFAZIO, PETER
· Mar 23, 2021
 D
DeLauro, Rosa L.
Connecticut · Mar 23, 2021
 D
Jayapal, Pramila
Washington · Mar 23, 2021
Jones, Mondaire
· Mar 23, 2021
 D
Neguse, Joe
Colorado · Mar 23, 2021
 D
Norton, Eleanor Holmes
District of Columbia · Mar 23, 2021
 D
Ocasio-Cortez, Alexandria
New York · Mar 23, 2021
 D
Omar, Ilhan
Minnesota · Mar 23, 2021
 D
Pocan, Mark
Wisconsin · Mar 23, 2021
 D
Pressley, Ayanna
Massachusetts · Mar 23, 2021
 D
Raskin, Jamie
Maryland · Mar 23, 2021
 D
Schakowsky, Janice D.
Illinois · Mar 23, 2021
 D
Tlaib, Rashida
Michigan · Mar 23, 2021
 D
Welch, Peter
Vermont · Mar 23, 2021
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 2148: Prescription Drug Price Relief Act of 2021. 117th Congress. Open America. https://openamerica.io/bill/117-HR-2148/
MLA
"H.R. 2148: Prescription Drug Price Relief Act of 2021." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-HR-2148/.
Bluebook (legal)
H.R. 2148, 117th Cong. (2026), https://openamerica.io/bill/117-HR-2148/.
Markdown link
[H.R. 2148: Prescription Drug Price Relief Act of 2021](https://openamerica.io/bill/117-HR-2148/)
Report a problem